Cranford Hospice is Hawke's Bay's leading palliative care provider. Our dedicated team is available 24 hours a day, seven days a week.
---------------------------
AXA
axaglobalhealthcare.com
Go further with international health insurance. Global support for people who think a little bigger
---------------------------
APOLLONIO
apollonion.com
The Apollonion Private Hospital is an ultra-modern Hospital purposely built to offer the best medical care to its patients.
---------------------------
Durbin
durbinglobal.com
Specialist medical suppliers in sourcing and distributing pharmaceuticals, medical equipment and consumable supplies.
---------------------------
Self
self.com
Women Magazine on Fitness, Health, Food, Beauty & more.
---------------------------
Easyway
allencarr.com
Allen Carr Easyway International operates clinics in more than 150 cities in over 50 countries worldwide.
---------------------------
id Hospital
idhospital.com
All kinds of plastic surgeries at affordable cost.
---------------------------
Al Zahra Hospital
alzahra.com
Al Zahra Hospital Sharjah is the first and the largest private general hospital in the UAE with both inpatient and outpatient treatment at an international standard,
---------------------------
Kunming Children�s Hospital
crhealthcare.com.hk
Kunming Children Hospital integrates first aid, medical treatment, rehabilitation, health care, & scientific research.
---------------------------
UT Health
uthealtheasttexas.com
UT Health East Texas is passionate about delivering the highest quality care with unmatched compassion, outstanding service and innovative technology.
---------------------------
WORLD HOSPITAL DIRECTORY
Health News Medical The Economic Times India - Healthcare
Aster DM Healthcare will invest Rs 480 crore to establish a 430-bed multispecialty hospital in Sarjapur, Bengaluru. The hospital, spanning 4 lakh sq ft, will be developed in two phases, with 300 beds operational by the second half of FY27 and the remaining 130 beds by FY29.
Manipal Hospitals, IHH Healthcare, and Blackstone-owned Quality Care India are among the frontrunners vying for Sahyadri Hospitals, Maharashtra's largest hospital chain, with bids ranging from ₹4,500-5,000 crore. Ontario Teachers’ Pension Plan Board is divesting the chain amid a wave of PE-led consolidation in India's rapidly growing healthcare sector, which is witnessing significant investment and expansion.
The introduction of weight-loss medications like Mounjaro and Wegovy in India may lead to a decrease in bariatric surgeries as obese individuals with a BMI of 30-35 may opt for drugs first. While surgeries can result in 70-80% weight loss, drugs offer a less invasive option, though potentially less effective at 15-20%.
Aster DM Healthcare has finalized the acquisition of a 5% stake in Quality Care India Ltd (QCIL) through a share swap with BCP Asia II TopCo IV Pte Ltd and Centella Mauritius Holdings Limited. This acquisition marks the initial phase of the strategic merger between Aster DM Healthcare and Quality Care India.
Max Healthcare is set to invest ₹6,000 crore over the next three years to expand its network, aiming to reach 25 hospitals by 2025. The expansion includes new facilities in Saket, Nanavati, Mohali, and Gurugram, with a recent inauguration of a 300-bed hospital in Dwarka.
Max Healthcare will invest Rs 6,000 crore by 2028 to add 3,700 beds across India, increasing its facilities to around 30 hospitals. The expansion, funded internally, includes the recent inauguration of a 300-bed hospital in Dwarka, Delhi, and upcoming facilities in Mohali, Mumbai, and Saket. The company remains open to acquisitions beyond its organic growth plans.
Global Health, known for its Medanta hospitals, is set to invest approximately Rs 500 crore in establishing a 400-bed super speciality hospital in Guwahati, Assam. The board has approved the land purchase for Rs 30 crore. This initiative aims to enhance healthcare infrastructure, offering advanced medical care across 20 specialities to over 50 million people in Assam and neighboring states.
Piyush Goyal stated that India frequently receives requests to extend pharmaceutical patents for minor modifications. He criticized this practice, known as 'evergreening,' for prioritizing corporate profits over global healthcare access. Goyal highlighted Ayushman Bharat scheme, providing free healthcare to over 620 million people. He emphasized India's commitment to healthcare driven by compassion, not profit.
Reckitt Benckiser's CEO, Kris Licht, highlighted India as a key growth driver, anticipating sustained strong volume growth alongside China. The company's success is fueled by strong organic performance in germ protection (Dettol) and intimate wellness (Durex). Reckitt's strategic alignment with India's public health goals has deepened market penetration.
India's drug advisory board is considering restricting over-the-counter medication sales to prevent misuse and ensure patient safety. The proposal limits OTC sales to 27 drugs, including antipyretics and painkillers, with dosage and quantity restrictions. The board aims to increase accessibility while ensuring patient safety by excluding several currently available drugs and recommending smaller pack sizes for safe use.
India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal volumes and a 326% surge in values for Q1 2025. Despite a slight quarterly dip due to macroeconomic factors, high-value deals are on the rise, particularly in M&A and PE activity, signaling confidence in scalable models and strategic acquisitions.
The National Academy of Medical Sciences (NAMS) has recommended categorising cancer as a notifiable disease to improve prevention and treatment in India. The organisation emphasised the importance of indigenous HPV tests and vaccines in cancer screening, alongside strengthening diagnostic infrastructure. Key recommendations include early detection, timely treatment, and a national cancer screening programme to reduce mortality rates, particularly from cervical and breast cancer.
Shivinder Mohan Singh, the former Fortis Healthcare promoter, has sought personal insolvency before the NCLT, citing liabilities exceeding assets. Facing a Rs 3,500 crore recovery to Daiichi Sankyo, Singh's assets are largely attached or devalued due to litigation and mismanagement within RHC Holding.
India is set to promote kidney swap transplants nationwide, aiming to increase transplant numbers by up to 15%. Following a directive from NOTTO, states and union territories are encouraged to implement swap transplants, a practice already recognized but underutilized. The initiative includes a standardized document list and the potential creation of a national swap registry.
A recent study indicates yoga is as effective as strengthening exercises for managing knee osteoarthritis, offering improvements in pain, quality of life, and depression. Experts highlight yoga's comprehensive approach, addressing mental health, balance, and joint mobility. Both yoga and resistance training achieve similar physiological goals through different methods, promoting synovial fluid circulation and reducing joint pressure.
The government has prohibited cough syrups containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four due to safety concerns. Drug regulators are mandating manufacturers to include explicit warnings on labels and packaging. This decision follows recommendations from India's apex drug body after examining the fixed-dose combination.
Assam Chief Minister Himanta Biswa Sarma is undertaking steps to transform Gauhati Medical College and Hospital into one of India's largest. The upcoming Mother and Child Care Hospital on GMCH premises will offer specialized pediatric care with 800 beds.
The Delhi High Court is reviewing RHC Healthcare's challenge to the 'Fortis' trademark sale to Fortis Healthcare, alleging undervaluation. RHC seeks an independent valuation, claiming the Rs 200 crore sale was based on an erroneous report by Daiichi Sankyo. While the court didn't halt the sale, further actions regarding the Fortis brand are subject to the appeal's outcome.
India’s healthcare spending is projected to rise from 3.3% to 5% of GDP by 2030, according to a CareEdge report. The sector is poised for major transformation driven by investments, government initiatives, and demographic shifts.
Investors are increasingly scrutinizing India's healthcare sector, including pharma companies and hospitals, due to concerns about potential malpractices and regulatory scrutiny. They are conducting in-depth due diligence, examining doctor-management relationships, referral practices, and the appropriateness of treatments. This heightened scrutiny is driven by negative consumer feedback and stricter regulations, prompting companies to enhance employee background screening.
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle diseases and increased affordability. Semaglutide, particularly Rybelsus from Novo Nordisk, dominates the market, accounting for 69% of sales. The introduction of Mounjaro by Eli Lilly has further fueled acceptance, with Novo Nordisk planning to launch Wegovy soon.
Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies introducing their versions. This influx has significantly increased sales, driven by prices that are 80-90% lower than the original. The increased affordability is expected to improve access for a wider population, with further market expansion anticipated.
Non-metro locations, such as Lucknow , Vizag, Jaipur, Cochin, Siliguri, Guwahati, Bhubaneswar and Patna, private equity investors believe, hold great growth potential in healthcare, in lockstep with an increasing affordability quotient in tier- 2 or 3 towns, and a greater availability of qualified doctors and specialists.
India's health insurance sector is experiencing a paradox; while premium collections have soared by 20%, new policyholder growth lags at 5%. Rising premiums, linked to medical inflation and increased claim sizes, deter renewals and new sign-ups, complicating affordability and access.
The Union Health Ministry plans to initiate capacity-building activities for frontline workers administering the HPV vaccine to girls aged 9-14 years to prevent cervical cancer. Following recommendations, the Ministry is finalizing strategies for this initiative. India accounts for a significant portion of global cervical cancer cases, with the vaccines aimed at addressing this major health issue.
Rising health insurance premiums and frequent claim rejections have led more Indians to drop their coverage. Despite the introduction of GST and government schemes, escalating costs leave many struggling to afford insurance, prompting calls for regulatory reforms to stabilize healthcare expenses.
Kerala Health Minister Veena George announced the introduction of digital payment systems in 313 government hospitals to facilitate various service fee transactions. This system, part of the e-health initiative, employs POS devices from State Bank of India and Canara Bank, and includes capabilities such as the M-Health app and QR code-based ticket booking.
People Tree Hospital secures a ₹220 crore ($25M) investment from BlackRock to expand to 400 beds, enhancing super-specialty and oncology care in Bengaluru
US President Donald Trump has imposed a 27% reciprocal tariff on Indian medical device exports, challenging the sector's growth. Indian export figures stood at $714.38 million compared to $1,519.94 million in imports from the U.S., raising concerns over competitiveness and regulatory barriers.
Fortis Healthcare has acquired the Fortis trademark from its former promoters, the Singh brothers, for Rs. 200 crore through a court-sanctioned auction. The trademark was involved in a litigation case with Japan's Daiichi Sankyo. Fortis Healthcare, now owned by IHH Healthcare, operates a network of 26 hospitals nationwide.
Fair trade regulator CCI has approved 360 ONE and Claypond Capital Partners' joint proposal to acquire stakes in API Holdings. This transaction involves purchasing compulsorily convertible preference shares from MEMG Family Office LLP, indicating oversight to prevent unfair business practices and ensure fair competition.
Ankura Hospitals has secured Rs 165 crore in funding from the Asian Development Bank. This strategic investment will enhance its pediatric, maternity, and gynecology services, enabling the Hyderabad-based chain to expand its facilities and strengthen its presence in key cities across India.
Global investment firm KKR is in talks to acquire Leixir Dental Laboratory Group from Comvest Investment Partners at a valuation of $200-$250 million. Leixir, founded in 2013, offers various dental solutions and operates facilities in the US and India. Deloitte is advising on the sale process.
Digital skills are crucial for healthcare professionals, with growing fields like telemedicine, AI-driven diagnostics, and data analytics. Continuous learning in electronic health records, cybersecurity, and emerging technologies like 3D printing and robotics is vital for those seeking to stay relevant and succeed in the evolving healthcare landscape.
Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, potentially reducing it by 85%-90%. With heart disease cases surging in India, this phase 3 trial drug promises significant cardiovascular benefits, requiring only once-a-year administration. It's crucial, given the rising heart ailments in the region.
US President Trump's decision to suspend USAID programmes and fund cuts by other countries could lead to 10.8 million new HIV infections and 2.9 million HIV-related deaths by 2030 in low-and-middle-income countries. Major donor funding cuts may reverse decades of progress against HIV/AIDS, especially in sub-Saharan Africa and among vulnerable populations.
Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, recently launched in India. Priced significantly lower than in the US, Mounjaro's introduction anticipates strong demand in the country with over 100 million obese and diabetic individuals.
India has developed its first indigenous MRI machine to be installed at AIIMS Delhi by October for trials, reducing dependency on imports by 80-85%. An MoU was signed with SAMEER for the installation. The Ministry of Electronics and Information Technology is spearheading this technological advancement aimed at achieving self-reliance in medical technology.
Gnanamma Healthcare Centre in Jaidoh, West Khasi Hills celebrates its transition to a near net-zero electricity facility with a new 6.05kW solar plant and battery energy storage. This upgrade ensures reliable power, especially for critical services like vaccine storage and emergency care, reducing carbon emissions and setting an example for sustainable healthcare in the region.
India plans to develop cost-effective left ventricular assist devices (LVADs) to aid end-stage heart failure patients while they wait for donor hearts. With an estimated 50,000 patients needing heart transplants annually but a severe shortage of donor hearts, indigenously made LVADs could reduce costs and increase foreign medical visitors. Development could take over five years with necessary approvals.
Metropolis Healthcare plans to acquire 2-3 cos annually to boost its presence in northern and eastern India. The firm aims to enhance its specialty testing business, focusing on various medical fields. The acquisitions will be funded by internal accruals, leveraging their debt-free status. Future growth includes expanding lab networks and using advanced diagnostics technology.
Mark Suzman, CEO of the Gates Foundation, sees the current global funding challenges as an opportunity for India to lead, particularly in health and development. Amid funding cuts from the US, UK, and France, Suzman remains optimistic about mobilizing resources for life-saving initiatives, highlighting India's cost-effective innovations.
The Association of Indian Medical Device Industry (AiMeD) has requested the government to impose safeguard duties on 12 medical device categories to shield domestic manufacturers from cheap imports. AiMeD highlighted a significant increase in imports, notably in syringes and needles, primarily from China, the US, and Singapore.
Health Minister JP Nadda emphasized the government's commitment to enhancing healthcare through policies incorporating AI for TB detection, modern cancer treatments, and mental health teleconsultation. The goal is to increase health expenditure to 2.5% of GDP, currently at 1.84%, showcasing substantial achievements in improving maternal and child mortality rates.
Entero Healthcare Solutions launched the 'HealthEdge' program to modernise retail pharmacies and improve efficiency for over 86,000 chemists. The company also acquired the Aayu Chemist app and Medcords platform, aimed at enhancing profits and customer engagement. Entero reported significant revenue and profit growth in FY 2025 Q3.
The Indian government is considering lowering tariffs on US medical devices to mitigate potential US tariff threats on Indian exports. While this aims to ease trade tensions, industry experts express concerns about the impact on India's self-reliance. Stakeholders suggest reciprocal market access as Indian exporters face high regulatory barriers in the US.
Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-income countries, patients in whom 'B-cell' tumours continue to grow following a period of remission (relapse), or do not respond to treatment (refractory), suffer from poor outcomes due to an absence of effective therapies.
AIIMS in New Delhi is experiencing severe staff shortages, with hundreds of vacant posts for doctors and faculty members. A parliamentary committee has urged the health ministry to offer competitive compensation and prioritize the filling of these positions. Additionally, the slow progress of AIIMS' expansion projects has been criticized.
Frequent use of steroid-based treatments for respiratory issues, allergies, and skin conditions can heighten the risk of glaucoma. Experts at AIIMS stress the importance of regular eye check-ups for early detection. Lifelong care and awareness programs at the primary care level are essential for preserving vision.
A study by AIIMS reveals that bio-enhanced curcumin, found in turmeric (haldi), effectively treats mild to moderate dry eye disease by improving tear stability and reducing inflammation. The clinical trial showed significant improvements in tear metrics and symptoms, suggesting a natural, side-effect-free alternative treatment.
Home
Contact
Back to "Medical Updates - Homepage"
